glp 1 agonist liver disease Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Treatment? Current status of glucagon-like peptide-1

Description

Omega-3 fatty acids and inflammatory processes: From molecules to man

Mol Metab 64:101550

Proc Natl Acad Sci

In recent years, pharmacological interventions have emerged as important adjuncts to traditional weight loss approaches

These resources include: A CISP Checklist Implementing Revised List (available now - originally published January 2021) Athlete and ASP Guide to the 2025 List (available now) Languages and Formats The 2025 Prohibited List, the 2025 Summary of Modifications and Explanatory Notes, and the 2025 Monitoring Program are available for download on WADAs website in English, French, and Spanish